Regional EAC Drug Anti-Counterfeit Bill Still Implicates Generics

The anti-counterfeit drugs bill under consideration for the East Africa Community (EAC) is expected to have significant consequences for the region's generic drugmakers and exports, as well as multinational pharmaceutical firms prospecting for new markets. Patients will also be affected by restricted access to medicines in key areas including tuberculosis (TB), malaria and HIV/AIDS.

To read the full article, please choose one of the following options: